Full Breakdown
Caribou Biosciences Halts Development of Off-The-Shelf CAR-T Therapy for Lymphoma
By Drooid · · How we work
Core Event: Company Announces Shutdown
Caribou Biosciences, a Berkeley, Calif.–based biotech founded from the laboratory of CRISPR pioneer Jennifer Doudna, disclosed that it will cease all clinical development of its two CRISPR-based CAR-T products, including vespa-cel for advanced B-cell non-Hodgkin lymphoma. The decision follows the company’s inability to secure sufficient financing for a planned Phase 3 trial. CEO Rachel Haurwitz told STAT that raising the capital required for the late-stage study proved too difficult, prompting the shutdown.
Background and Program Development
Caribou’s off-the-shelf CAR-T platform was designed to create “universal” cell therapies that could be manufactured at scale, avoiding the patient-specific manufacturing process used by earlier CAR-T approaches. Over the past year, the firm worked with the U.S. Food and Drug Administration to finalize the design of a pivotal Phase 3 trial for vespa-cel, positioning the therapy as a potential treatment for patients with relapsed or refractory B-cell lymphoma.
Financial and Clinical Hurdles
The company’s inability to raise the necessary funds reflects broader financing challenges for late-stage biotech programs, especially those involving novel gene-editing technologies. Without the capital to launch the Phase 3 study, Caribou cannot generate the efficacy and safety data required for regulatory approval, leading to the termination of its lymphoma program.
Implications for CRISPR-Based Immunotherapies
The shutdown underscores the financial risk inherent in advancing CRISPR-engineered cell therapies to late-stage trials. While the technology remains promising, investors and developers may exercise heightened caution when allocating resources to large-scale clinical programs. The cessation of vespa-cel’s development may also slow the broader industry momentum toward off-the-shelf CAR-T solutions, prompting other firms to reassess funding strategies and trial designs.